Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05375721
Other study ID # YX2021-152(F1)
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 23, 2022
Est. completion date May 1, 2024

Study information

Verified date September 2022
Source The Second Hospital of Anhui Medical University
Contact Chunxia Huang, Ph.D
Phone +8613500512159
Email huangchunxia@ahmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Postoperative nausea and vomiting (PONV) is particularly one of the most common complications after laparoscopic sleeve gastrectomy (LSG). It can lead to serious adverse events and delayed activity, and prolong the time of rehabilitation and discharge. Numbers of studies have been focused on identifying risk factors and therapies of PONV. Unfortunately, there' no consistent comments for PONV prevention in women after LSG. Notably, Zusanli (ST36) acupoint and anisodamine have been evidenced to treat various gastrointestinal conditions. The primary outcome of this study was to evaluate the impact of anisodamine injection in ST36 on PONV in women following bariatric surgery.


Description:

At the onset of this investigation, we have already identified several methodologic issues, such as the timing of the acupuncture intervention, sample size, perioperative anesthetic techniques, and appropriate control groups. All subjects were randomly assigned to the following two groups: ST36 acupoint injection group (bilateral ST36 acupoint injection with scopolamine); pharmacoprophylaxis group (bilateral ST36 injection with normal saline). The primary outcome of this study was the total incidence of PONV during the hospital and after the discharge. Participants were randomly assigned into different groups according to the computer-generated randomization sequence (http://www.randomization.com). Patients, surgeons, care givers, anesthesiologists, nursing staff, and outcomes assessor, were all blinded to the group assignment.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date May 1, 2024
Est. primary completion date February 1, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Female patients with an American Society of Anesthesia (ASA) physical status I-IV 2. Scheduled for elective bariatric surgery 3. Written informed consent was obtained Exclusion Criteria: 1. Patients with contraindications for acupoint injection 2. Difficulty in communicating with patients 3. Allergic diathesis for drugs used in the study or serious illness (heart, lung, kidney, or liver, et. al) 4. Coagulation dysfunction 5. Pre-existing psychological or neurological disorder 6. Pre-use medicine before surgery that would interferenced objective assessment (including the use of opioids, antiemetics or glucocorticoids) 7. Gastroesophageal reflux disease

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
ST36 acupoint injection
ST36 is located on the lateral surface of leg, 3 cun distal to the lower border of the patella, 1 finger-breadth lateral to the anterior crest of the tibia, between the tibialis anterior muscle and the tendon of the extensor digitorum longus. (The breadth of patient's middle finger was the proportional unit of measure "the cun", defined as the distance between the two medial ends of the creases of the interphalangeal joints when the patient's middle finger is flexed).

Locations

Country Name City State
China Beijing Chao-Yang Hospital, Capital Medical University Beijing
China The First Affiliated Hospital of Jinan University Guangzhou Guangdong
China The Second Hospital of Anhui Medical University Hefei Anhui
China Jiangsu Province Hospital Nanjing Jiangsu
China Huashan Hospital Affiliated to Fudan University Shanghai
China The Affiliated Hospital of Xuzhou Medical University Xuzhou Jiangsu
China Henan Provincial People's Hospital Zhengzhou Henan

Sponsors (7)

Lead Sponsor Collaborator
The Second Hospital of Anhui Medical University Beijing Chao Yang Hospital, First Affiliated Hospital of Jinan University, Henan Provincial People's Hospital, Huashan Hospital, The Affiliated Hospital of Xuzhou Medical University, The First Affiliated Hospital with Nanjing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Consumption of propofol The total consumption of propofol during the surgery During the bariatric surgery
Other Consumption of remifentanil The total consumption of remifentanil during the surgery During the surgery
Other Consumption of sufentanil The total consumption of sufentanil during the surgery During the surgery and postoperative 1-3 days
Other Duration of anesthesia From beginning to the end of anesthesia At the end of anesthesia
Other Duration of surgery From beginning to the end of surgery At the end of surgery
Primary The incidence and severity of PONV The incidence and severity of PONV after bariatric surgery At 0-2 hours after surgery
Primary The incidence and severity of PONV Total usage of rescue antiemetic drugs after bariatric surgery At 2-6 hours after surgery
Primary The incidence and severity of PONV The incidence and severity of PONV after bariatric surgery At 6-12 hours after surgery
Primary The incidence and severity of PONV The incidence and severity of PONV after bariatric surgery At 12-24 hours after surgery
Primary The usage of rescue antiemetic drugs Total usage of rescue antiemetic drugs after bariatric surgery During 3 months after bariatric surgery
Secondary 15-item Quality of Recovery(QoR-15) QoR-15 will be used to evaluate recovery quality after anesthesia, including 15 items covering sleep, satisfaction, emotion and pain et. al,total score ranges from 0 to 150,the higher score means the higher quality of recovery. Postoperative 24 hours
Secondary Postoperative pain Patients will be asked about their pain level at rest and moving on a numeric rating scale (0=no pain,10=worst pain imaginable) . At 0-24 and 24-72 hours after surgery
Secondary Consumption of analgesics Cumulative analgesic consumption after surgery During 3 months after bariatric surgery
Secondary Ambulation time Interval time of patients' transit from bed rest to ambulation after surgery Postoperative 1-3 days
Secondary Postoperative food and water intake time Duration of eating and drinking after surgery Postoperative 1-3 days
Secondary Postoperative hospitalization duration Days of hospital staying after surgery 2 weeks after surgery
Secondary Pittsburgh sleep quality index Pittsburgh sleep quality index will be used to evaluate quality of sleep. The higher score means the lower quality of sleep. Before surgery and at postoperative 3 months
Secondary Gastrointestinal Symptom Rating Scale Gastrointestinal symptom rating scale (GSRS) will be used to assess gastrointestinal function. The score ranges from 0 to 45. The higher score means poorer gastrointestinal function . Before surgery and at postoperative 3 months
Secondary Hamilton depression rating scale Hamilton depression scale (HAMD) will be used to assess depression. HAMD 24 item version score range 0-96. The higher score means the higher possibility of depression. Before surgery and at postoperative 3 months
Secondary Hamilton anxiety rating scale Hamilton anxiety scale (HAM-A) will be used to assess anxiety. Total score ranges from 0 to 56, the higher the score is, the more serious the anxiety is. Before surgery and at postoperative 3 months
Secondary The MOS item short from health survey ,SF-36 Concise health status scale Before surgery and at the postoperative 3 months.The scale consists of 36 items,divided into 8 sections,score of each section ranges from 0 to 100, the higher the score is, the healthier is.
See also
  Status Clinical Trial Phase
Completed NCT04466046 - The Effect on Anxiolytics With Type of Antiemetic Agents on Postoperative Nausea and Vomiting in High Risk Patients
Completed NCT03139383 - Dextrose Containing Fluid and the Postoperative Nausea and Vomiting in the Gynecologic Laparoscopic Surgery N/A
Recruiting NCT04069806 - Preoperative Oral Carbohydrate for Nausea and Vomiting Prevention During Cesarian Section N/A
Completed NCT04043247 - Transcutaneous Electrical Acupoint Stimulation for Prevention of Postoperative Nausea and Vomiting N/A
Terminated NCT01975727 - Dexamethasone for the Treatment of Established Postoperative Nausea and Vomiting Phase 2
Completed NCT03662672 - Rib Raising for Post-operative Ileus N/A
Completed NCT00090155 - 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-090)(COMPLETED) Phase 3
Completed NCT02480088 - Comparison of Palonosetron and Ramosetron for Preventing Patient-controlled Analgesia Related Nausea and Vomiting Following Spine Surgery; Association With ABCB1 Polymorphism Phase 4
Recruiting NCT06137027 - Cannabidiol Oil Extract for Prevention of Postoperative Nausea and Vomiting Early Phase 1
Not yet recruiting NCT05529004 - A 6 Months Double Blind Trial to Prevent PONV in Laparoscopic Cholecystectomy Phase 2
Completed NCT02944942 - Risk Factors for Postoperative Nausea/Vomiting N/A
Recruiting NCT02571153 - Low Doses of Ketamine and Postoperative Quality of Recovery Phase 4
Completed NCT02550795 - Dexmedetomidine or Dexmedetomidine Combined With Dexamethasone on Postoperative Nausea and Vomiting in Breast Cancer N/A
Completed NCT02449291 - Study of APD421 as PONV Treatment (no Prior Prophylaxis) Phase 3
Recruiting NCT01442012 - Utility of Acupuncture in the Treatment of Postoperative Nausea and Vomiting in Ambulatory Surgery N/A
Completed NCT01478165 - Comparison of TIVA (Total Intravenous Anesthesia) and TIVA Plus Palonosetron in Preventing Postoperative Nausea and Vomiting N/A
Unknown status NCT01268748 - Single Port Versus Four Ports Laparoscopic Cholecystectomy and Early Postoperative Pain N/A
Completed NCT02143531 - Intravenous Haloperidol Versus Ondansetron for Treatment of Established Post-operative Nausea and Vomiting Phase 4
Completed NCT00734929 - Aprepitant With Dexamethasone Versus Ondansetron With Dexamethasone for PONV Prophylaxis in Patients Having Craniotomy Phase 4
Withdrawn NCT00151099 - Safety of Preoperative Oral Administration of a High Caloric Drink With Protein Phase 4